Navigation Links
Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma
Date:11/1/2009

Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT). This study was pre-published online today in Blood, the official journal of the American Society of Hematology.

Washington (PRWEB) November 1, 2009 -- Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT). This study was pre-published online today in Blood, the official journal of the American Society of Hematology.

Lymphoma is a cancer of white blood cells called lymphocytes that are largely responsible for maintaining the body's immunity, and EBV is one of the most common human viruses that can have a long-lasting impact on the body's immune system. Immune-compromised patients who receive HSCT, especially from mismatched donors or matched but unrelated donors, may be at higher risk of developing EBV-lymphoma than other patients. Previous studies have suggested that EBV-lymphoma occurs most often in the first few months post-transplant.

The researchers hypothesized that aggressive EBV-lymphomas may be responsive to control or eradication with EBV-specific cytotoxic T lymphocyte (CTL) treatment. (CTLs are highly specialized white blood cells that build the body's defenses against disease.) To test their theory, the team infused EBV-specific CTL lines into two groups of patients: those who were undergoing HSCT and were at high risk of developing EBV-lymphoma, and patients who had already developed lymphoma. The study reported that CTL treatment successfully prevented the development of EBV-lymphoma in all 101 patients in the at-risk group who received the therapy prophylactically and achieved sustained complete remission in 11 of the 13 patients (85 percent) treated therapeutically (those who already had the disease).

"Therapy with EBV-specific CTLs was effective for these severely immunocompromised patients. The CTLs successfully reached tumors, multiplied, and were able to kill the tumor cells," said lead study author Helen Heslop, MD, of the Center for Cell and Gene Therapy at Baylor College of Medicine, The Methodist Hospital, and Texas Children's Hospital.

While the successful outcomes result from a number of factors in the study, the researchers attribute some of the success of the trial to the time of treatment. The CTL lines were infused soon after stem cell transplantation, when the existing white blood cell count was still low and was not quickly regenerating, allowing the infused cells to more quickly multiply and mediate anti-viral and anti-tumor effects. In addition, by marking and tracking the CTL genes, the team was able to demonstrate that the cells could survive for up to nine years in the body, conferring long-term protection.

With strong clinical outcomes, the study team is working to determine the most appropriate role and timing for CTL infusions. Some newer therapies (such as monoclonal antibodies) offer prophylactic and therapeutic options but cannot offer long-term protection. Therefore, treatment with CTLs may be reserved for the highest risk patients - those with a diagnosis of immune deficiency or a history of EBV-lymphoma, or those who develop elevated EBV levels after therapy with monoclonal antibodies.

Importantly, the study found that this type of therapy is not only effective, but economically advantageous. A preliminary analysis showed that a patient-specific CTL line can be manufactured, tested, and infused for approximately $6,000, a cost that compares well with other modalities used in the treatment of EBV-lymphoma. Moreover, the team determined that it is possible to manufacture cells in one location and ship them to another center for infusion, with reproducible and consistent results and clinical outcomes.

"It's important to note that this promising therapy is not only effective, but it is also a cost-effective option for high-risk patients," said Dr. Heslop.

Reporters who wish to receive a copy of the study or arrange an interview with Dr. Heslop may contact Patrick C. Irelan at 202-776-0544 or pirelan(at)hematology(dot)org.

The American Society of Hematology (www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. ASH provides Blood: The Vital Connection (www.bloodthevitalconnection.org), a credible online resource addressing bleeding and clotting disorders, anemia, and cancer. The official journal of ASH is Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online.

# # #

Read the full story at http://www.prweb.com/releases/2009/11/prweb3140794.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimers Immunotherapy Program and Equity Investment
2. Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimers Immunotherapy Program and Equity Investment
3. Immunotherapy effective against neuroblastoma in children
4. Sublingual immunotherapy for inhalant allergies deserves deeper consideration
5. Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer
6. Device aims to decrease wait period for patients needing immunotherapy
7. A new light on tumor immunotherapy for gastric cancer
8. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
9. 33rd Annual Hutch Holiday Gala Raises Millions for Cancer Immunotherapy Research
10. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
11. Towards improved immunotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers that ... of published author, Gene Gaapf, a retired truck driver, and a long-time writer, whose ... since high school and have many different titles,” Gaapf mentions about his different works. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... an On-demand E-learning system for Clinical and Regulatory education for Physicians, Physician ... on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. , The ...
(Date:1/19/2017)... ... , ... This month, the CEO and Clinical Director of Sober Living Outpatient, ... in Delray Beach, Florida has been changed from Sober Living Outpatient to ‘SLO Recovery ... Hoffman and Chris Farley are dying from heroin overdoses, but thousands of unnamed kids ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... Cosmetic ... of plastic surgery procedures in order to make it easier for their readers to ... of the body they impact as well as the techniques used on those particular ...
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business ... new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba ... to facilitate a recapitalization of MedPro led by Harren Equity Partners. Brightwood ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... January 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in Israel ... Wound care is $2 5 billion ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of ... Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia for the ...
(Date:1/19/2017)... , Jan. 18, 2017 The drug ... billion by 2021 from USD 1,179.20 billion in 2016, ... Increasing prevalence of chronic diseases, increasing demand for ... factors driving the growth of this market. Whereas, self-administration ... generic drugs offer significant growth opportunities for players operating ...
(Date:1/18/2017)... and PUNE, India , January 18, 2017 ... Market Research, titled, "Breast Imaging Technologies Market by Type: Global ... breast imaging technologies market size was valued at $2,544 million ... 2022, growing at a CAGR of 8.4% from 2016 to ... Europe together accounted for over three-fourths market share ...
Breaking Medicine Technology: